Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
Portfolio Pulse from Vandana Singh
Truist Securities initiated coverage on Longboard Pharmaceuticals (NASDAQ:LBPH), highlighting its high-value epilepsy assets. The company plans to advance its lead drug, bexicaserin, into Phase 3 trials. Bexicaserin has shown promising results in reducing seizures and has received FDA Breakthrough Therapy designation. Truist rates LBPH as a Buy with a $60 price target, citing bexicaserin's superior safety and potential to expand the epilepsy market.
September 10, 2024 | 6:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities initiated coverage on Longboard Pharmaceuticals with a Buy rating and a $60 price target. The company's lead drug, bexicaserin, is advancing to Phase 3 trials and has shown promising results in reducing seizures. Bexicaserin's superior safety profile compared to market leader Fintepla could expand the epilepsy market.
The initiation of coverage by Truist Securities with a Buy rating and a $60 price target is a strong positive signal for LBPH. The promising results of bexicaserin, along with its FDA Breakthrough Therapy designation, enhance its potential in the epilepsy market. The comparison to Fintepla, highlighting superior safety, suggests a competitive advantage.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100